Metabolic associated liver disease

被引:1
|
作者
Testino, Gianni [1 ,3 ]
Pellicano, Rinaldo [2 ]
机构
[1] Polyclin San Martino Hosp, Alcohol Reg Ctr, Unit Addict & Hepatol, ASL3 C-O, Genoa, Italy
[2] Molinette SGAS Hosp, Unit Gastroenterol, Turin, Italy
[3] Polyclin San martino Hosp, Alcohol Reg Ctr, Unit Addict & Hepatol, ASL3 C-O Padigl 10,Piazzale R Benzi 10, I-16132 Genoa, Italy
关键词
Alcohol drinking; Metabolic syndrome; Non-alcoholic fatty liver disease; Diabetes mellitus; type; 2; NONALCOHOLIC FATTY LIVER; ALCOHOL-USE; HEPATOCELLULAR-CARCINOMA; TRANSIENT ELASTOGRAPHY; BLOOD-PRESSURE; FIBROSIS; RISK; IDENTIFICATION; PERFORMANCE; MANAGEMENT;
D O I
10.23736/S0031-0808.22.04730-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In real practice the patient with liver disease is often the carrier of multiple etiological factors such as metabolic syndrome (MS) and alcohol consumption (AC). Their copresence is often underestimated and AC is not adequately studied. Traditionally to diagnose non-alcoholic fatty liver disease (NAFLD), AC must not exceed 30 gr for men and 20 gr for women per day. This limit should still be reduced, especially in relation to the AC and fibrogenesis ratio and also frequent misestimation of AC or unrecognized MS may underestimate multi caused liver injury. AC is a contributing cause of MS and alcoholic and non-alcoholic liver disease have a substantially overlapping histopathological picture. Moreover, AC and MS are cause and contributing cause of extra-hepatic morbidity and mortality. It can be concluded that the possible simplification of terminology at metabolic associated liver disease (MALD) makes clinical activity more usable and immediate, facilitates better communication and cooperation between scientific societies and specialists who apparently deal with different medical sectors, facilitates early identification of related hepatic and extra-hepatic pathology, allows to "see the person in a unitary way," to create more streamlined care pathways, to reduce the hospitalization rate with relative cost-benefit advantage and to create unitary prevention and health promotion policies.
引用
收藏
页码:555 / 563
页数:9
相关论文
共 50 条
  • [21] Metabolic Dysfunction-Associated Steatotic Liver Disease
    Ali, Sajjadh M. J.
    Lai, Michelle
    ANNALS OF INTERNAL MEDICINE, 2025, 178 (01) : ITC1 - ITC17
  • [22] Nutrients associated with metabolic dysfunction-associated steatotic liver disease
    Jeong, Seogsong
    JOURNAL OF HEPATOLOGY, 2024, 80 (02) : e81 - e82
  • [23] Dietary patterns associated with metabolic associated fatty liver disease protection
    Schophaus, Simon
    Creasy, Kate Townsend
    Clusmann, Jan
    Koch, Alexander
    Trautwein, Christian
    Schneider, Kai Markus
    Schneider, Carolin Victoria
    JOURNAL OF HEPATOLOGY, 2023, 78 : S636 - S636
  • [24] Metabolic-associated fatty liver disease and the risk of cardiovascular disease
    Zhang, Pengwei
    Dong, Xianhui
    Zhang, Wei
    Wang, Shiyin
    Chen, Chen
    Tang, Jiake
    You, Yao
    Hu, Siqi
    Zhang, Shenghui
    Wang, Chunyi
    Wen, Wen
    Zhou, Mengyun
    Tan, Tao
    Qi, Guanming
    Li, Li
    Wang, Mingwei
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2023, 47 (01)
  • [25] Metabolic-associated fatty liver disease (MAFLD) in coeliac disease
    Rispo, Antonio
    Imperatore, Nicola
    Guarino, Maria
    Tortora, Raffaella
    Alisi, Anna
    Cossiga, Valentina
    Testa, Anna
    Ricciolino, Simona
    Fiorentino, Andrea
    Morisco, Filomena
    LIVER INTERNATIONAL, 2021, 41 (04) : 788 - 798
  • [26] METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE IS ASSOCIATED WITH LIVER FIBROSIS IN HEPATITIS C
    Elgretli, Wesal
    Shengir, Mohamed
    Sasson, Solomon
    Agnihotram, V. Ramanakumar
    Ballesteros, Luz Esther Ramos
    Deschenes, Marc
    Wong, Philip
    Chen, Tianyan
    Kronfli, Nadine
    Keeshan, Alexa
    Tandon, Saniya
    Cooper, Curtis
    Sebastiani, Giada
    HEPATOLOGY, 2024, 80 : S382 - S383
  • [27] The metabolic profiles and body composition of lean metabolic associated fatty liver disease
    Cheng, Yu-Ming
    Kao, Jia-Horng
    Wang, Chia-Chi
    HEPATOLOGY INTERNATIONAL, 2021, 15 (02) : 405 - 412
  • [28] The metabolic profiles and body composition of lean metabolic associated fatty liver disease
    Yu-Ming Cheng
    Jia-Horng Kao
    Chia-Chi Wang
    Hepatology International, 2021, 15 : 405 - 412
  • [29] Elafibranor: A promising treatment for alcoholic liver disease, metabolic-associated fatty liver disease, and cholestatic liver disease
    Zhang, Hang
    Dong, Xuan
    Zhu, Lei
    Tang, Fu-Shan
    WORLD JOURNAL OF GASTROENTEROLOGY, 2024, 30 (40)
  • [30] The association of liver fibrosis and chronic kidney disease in patients with metabolic associated fatty liver disease
    Badawi, Rehab
    Abou Taira, Naglaa Samy Fahmy
    Hasby, Sara Essam
    Elkhalawany, Walaa
    Elrefaey, Waleed
    Khalf, Nahla Ahmed
    Okda, Hanaa Ibrahim
    SAUDI MEDICAL JOURNAL, 2024, 45 (10) : 1034 - 1040